anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The primary goal of this work is to identify biomarkers associated with lung squamous cell carcinoma and assess their potential for early detection of lymph node metastasis.
METHODS: This study investigated gene expression in lymph node metastasis of lung squamous cell carcinoma using data from the Cancer Genome Atlas and R software. Protein-protein interaction networks, hub genes, and enriched pathways were analyzed. ZNF334 and TINAGL1, two less explored genes, were further examined through in vitro, ex vivo, and in vivo experiments to validate the findings from bioinformatics analyses. The role of ZNF334 and TINAGL1 in senescence induction was assessed after H2O2 and UV induced senescence phenotype determined using β-galactosidase activity and cell cycle status assay.
RESULTS: We identified a total of 611 up- and 339 down-regulated lung squamous cell carcinoma lymph node metastasis-associated genes (FDR < 0.05). Pathway enrichment analysis highlighted the central respiratory pathway within mitochondria for the subnet genes and the nuclear DNA-directed RNA polymerases for the hub genes. Significantly down regulation of ZNF334 gene was associated with malignancy lymph node progression and senescence induction has significantly altered ZNF334 expression (with consistency in bioinformatics, in vitro, ex vivo, and in vivo results). Deregulation of TINAGL1 expression with inconsistency in bioinformatics, in vitro (different types of lung squamous cancer cell lines), ex vivo, and in vivo results, was also associated with malignancy lymph node progression and altered in senescence phenotype.
CONCLUSIONS: ZNF334 is a highly generalizable gene to lymph node metastasis of lung squamous cell carcinoma and its expression alter certainly under senescence conditions.
1. Use of a LHRH analog or a combination of LHRH analogs and an antiestrogen with tissue-selective estrogenic effect which is selected from the group of compounds Raloxifen, Droloxifen, Centchroman, or their derivatives, for treatment of gynecological conditions, especially for treatment of endometrioses and myomas. 2. Use as claimed in claim 1, wherein the LHRH analog is a LHRH agonist or LHRH antagonist. 3. Use as claimed in claim 1 or 2, wherein the LHRH analog is selected from the group of compounds Leuprorelin, Centrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Try-D-Cit-Lan-Lys(Nor)-Pro-D-Ala-NH2, Ramorelix, Zoladex or their derivatives. 4. Use as claimed in one of claims 1 to 3, wherein the LHRH analog or combination of LHRH analogs is orally bioavailable. 5. Use as claimed in one of claims 1 to 4, wherein the LHRH analog is a non-peptidergic LHRH agonist or antagonist. 6. Use as claimed in one of claims 1 to 5, wherein the antiestrogen is of the Raloxifen type. 7. Use as claimed in one of claims 1 to 6, wherein the two active ingredients are present in separate forms of administration. 8. Use as claimed in one of claims 1 to 6, wherein the two active ingredients are present in common forms of administration. 9. Use as claimed in claim 7 or 8, wherein the LHRH analog and antiestrogen are used at the same time and/or sequentially in time.
The invention discloses a Chinese herbal medicine for treating liver cirrhosis. The Chinese herbal medicine is prepared from the following medicaments in part by weight: 35 to 45 parts of bupleurum, 35 to 45 parts of white paeony root, 25 to 35 parts of Chinese angelica, 45 to 55 parts of root of red-rooted salvia, 25 to 35 parts of tuber, 15 to 25 parts of largehead atractylodes rhizome, 15 to 25 parts of baical skullcap root, 45 to 55 parts of isatis indigostica fort, 5 to 15 parts of ground beetle and 15 to 25 parts of Indian buead. The Chinese herbal medicament is prepared by adding 1,500 parts of water into the medicaments; filtering and collecting supernate; and uniformly mixing the supernate obtained at three times of decoction, bottling the supernate, and sterilizing the supernate at high temperature for later use. The Chinese herbal medicine takes the root of red-rooted salvia as a monarch medicament, the bupleurum and the white paeony root as ministerial medicaments, the isatis indigostica fort, the Chinese angelica, the tuber and the largehead atractylodes rhizome as assistant medicaments and the baical skullcap root, the ground beetle and the Indian buead as guide medicaments. The Chinese herbal medicine for treating the liver cirrhosis is convenient to prepare and use and safe and does not have side effects. The Chinese herbal medicine has obvious effects of soothing liver, tonifying spleen, promoting circulation, removing meridian obstruction, activating blood to excrete water and treating the liver cirrhosis (hepatic stagnation). The Chinese herbal medicament has the treatment effect on most of over 30 patients with the liver cirrhosis during clinical use.
OBJECTIVE: The objective of this study is to elucidate the causal association between asthma and alopecia areata (AA) through the application of Mendelian randomization (MR) analysis, leveraging summary data from genome-wide association studies (GWAS). Additionally, it explores potential mediating factors.
MATERIALS AND METHODS: Mendelian randomization (MR) analysis was employed to investigate the causal relationship between asthma and AA using genetic instrumental variables (IVs) for asthma, 91 circulating inflammatory proteins, and AA extracted from large-scale GWAS. The primary analytical approach utilized the inverse-variance weighted (IVW) method, supplemented by weighted median and MR-Egger methods to assess robustness. Tests for heterogeneity and pleiotropy were conducted to ensure result reliability. Furthermore, the study examined the mediating role of circulating inflammatory proteins in the asthma-AA relationship.
RESULTS: The findings revealed an increased risk of AA among asthma patients (odds ratio (OR) = 14.070; 95% confidence interval (CI) = 1.410-140.435; P = 0.024). Interleukin-33 (IL-33) emerged as a significant mediator in the asthma-AA relationship, explaining 13.1% of the mediation effect. Bidirectional Mendelian randomization analyses did not establish a causal effect of AA on asthma occurrence.
CONCLUSION: This study, utilizing Mendelian Randomization, elucidates the causal link between asthma and AA, highlighting the mediating role of IL-33. These findings underscore the importance of considering AA risk in asthma management and offer insights for potential therapeutic strategies targeting IL-33. Future research should explore additional biomarkers and mediating mechanisms between asthma and AA to enhance treatment approaches and patient quality of life.
Patients will receive 7 days of oral azacitidine (CC-486) leading into cycle 1 day 1 of R-ICE chemotherapy. R-ICE chemotherapy may be administered as an inpatient or as an outpatient . Oral azacitidine will be administered on days 8-21 of cycles 1 and cycle 2. R-ICE will be administered per standard of care.
INTRODUCTION: Unlike the most common training approaches for bodybuilding, powerlifting programs are generally based on maximum and submaximal loads, putting enormous stresses on the lumbar spine. The flexion relaxation phenomenon evaluation is a clinical tool used for low back pain (LBP) assessment. This study aimed to evaluate the role of the flexion relaxation phenomenon in the analysis of LBP in the powerlifters.
METHODS: Healthy professional powerlifters participated in the study. In fact, we divided the participants into a LBP-low-risk group and a LBP-high-risk group, based on a prior history of LBP. Outcome measures included flexion relaxation ratio (FRR) and trough surface electromyography collected during trunk maximum voluntary flexion; furthermore, during a bench press lifting, we measured the height of the arched back (ARCH), using a camera and the Kinovea video editing software, to consider a potential correlation with the risk of LBP.
RESULTS: We included a group of 18 male (aged 24-39 y) powerlifters of 93 kg category. We measured a nonsignificant mean difference of ARCH between low-risk LBP group and high-risk LBP subjects. Curiously, maximum voluntary flexions were both above the threshold of 3.2 μV; therefore, with an absence of appropriate myoelectric silence, on the contrary, the FRR ratios were higher than 9.5, considering the presence of the phenomenon, exclusively for the low-risk group. The lumbar arched back measurement data did not report any association with the LBP risk, regarding the maximum voluntary flexion value, and even more than the FRR there is a relationship with the presence or the absence of LBP risk.
CONCLUSIONS: FRR could be considered as a useful parameter for studying the risk of LBP in powerlifting. The FRR index not only refers to the possible myoelectric silence of the lumbar muscles in trunk maximum forward flexion but also takes into account the energy value delivered by the lumbar muscles during the flexion. Furthermore, we can indicate that the size of the powerlifter ARCH may not be a determining factor in the occurrence of LBP.
The dual training group (DUAL) will receive aerobic exercise training and computerized cognitive training simultaneously. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. studies have shown that paliperidone is a P-gp substrate. in vitroin vivoIn vitro

Co-administration of INVEGA 6 mg once daily with carbamazepine, a strong inducer of both CYP3A4 and P-glycoprotein (P-gp), at 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state C and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. On initiation of carbamazepine, the dose of INVEGA should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of INVEGA should be re-evaluated and decreased if necessary. ®max®®

Paliperidone is metabolized to a limited extent by CYP2D6 . In an interaction study in healthy subjects in which a single 3 mg dose of INVEGA was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown. [see ] Clinical Pharmacology (12.3)®

Co-administration of a single dose of INVEGA 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the C and AUC of paliperidone. Dosage reduction for INVEGA should be considered when INVEGA is co-administered with valproate after clinical assessment. ®max®®

Pharmacokinetic interaction between lithium and INVEGA is unlikely. ®
The main goal of this program of research is to advance our understanding of how the severely damaged brain changes over the first 12-months post stroke. The prevalence and severity of stroke related arm disability is increasing and the prospect of optimal recovery is poor. Studies have demonstrated that stroke survivors with severe disability lack early indicators (\<7-days to \<1-month post-stroke) of a good prognosis, such as active movement at the shoulder and wrist and integrity of the corticospinal tract. This has propagated the clinical belief that this cohort are unlikely to functionally benefit from rehabilitation efforts. However, it is possible that indicators of potential for recovery - either neuroanatomical or clinical - may present in individuals with severe stroke later, that is beyond the early time-period. Indeed, there is increasing evidence of the potential for ongoing improvements in motor performance in response to intensive interventions that are undertaken 6-months or more post-stroke. This therefore, implies that there is some degree of untapped recovery potential. However, as very few studies have longitudinally explored the potential indicators of recovery in a severe cohort, the dynamic capacity of the severely damaged remains unknown. Thus, there is a need to determine 'who recovers', 'who does not recover', and 'why' to be able to promote optimal arm recovery in people with severe impairment after stroke. We will assess stroke survivors \<4-weeks, 3-months, 6-months and 12-months post stroke using a range of neuroimaging and clinical outcome measures. The findings from this study will build the foundations for more personalized health care options for people with severe arm impairment post stroke.
Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
The only specific procedures unique to this protocol is the collection of an additional 3ml or less of cerebrospinal fluid from a lumbar puncture already being performed and the collection of clinical information from the patients medical records. Lumbar puncture may be either a research procedure or a standard of care procedure, depending upon the reason for initiating the puncture. We will aliquot the additional fluid into a separate storage container and it will be maintained in the laboratory of Dr. Heiman-Patterson at -70 degrees. Clinical information including age, medical and neurological history, laboratory data, and pathologic information where indicated will be abstracted from the patient chart. All specimens and corresponding clinical information will be labeled with an identification number and sorted by diagnosis. There will be no patient identifying information kept with the specimens. The CSF sample may be used for studies performed by researchers at Drexel University College of Medicine or shared with collaborators. The CSF sample provided will only be used for projects that have approval by the IRB, but subjects will not be notified each time it is used for a study. If CSF sample is still available, consent can be withdrawn at any time by writing a letter to Dr. Heiman-Patterson requesting the withdrawal of the sample.

Researchers will request control and disease specific samples to use in various research studies. There are no DNA studies.
PROBLEM TO BE SOLVED: To obtain a photopolymerizable composition which has a sufficient tolerance of an operation time under the influence of environmental light and can be rapidly cured under the influence of light from a light irradiator to give a product of a high curing depth by adding a small amount of an α- alkylstyrene and/or an α-alkylstyrene dimer (C) to a photopolymerizable composition comprising a polymerizable vinyl monomer (A) and a photopolymerization initiator (B). SOLUTION: Component A used is a polymerizable vinyl monomer having an acryloyl group and/or a methacryloyl group, particularly desirably a mixed system comprising bisphenol A glycidyl methacrylate, bismethacryloylethoxyphenylpropane and triethylene glycol dimethacrylate. Component B used is a combination of a photosensitizer (e.g. α-diketone) with a reducing agent (e.g. tert. amine), and the photosensitizer is used in an amount to give a weight ratio to the reducing agent of 0.2-3. The mixing ratio is such that 0.1-3 pts.wt. component B and 0.01-1 pt.wt. component C are used per 100 pts.wt. component A.
PURPOSE:To remove noises exclusive of heart beat information and to improve the detection accuracy of the heart beats by providing a bioinformation detecting means to be embedded into a seat and vibration sensing means installed in the position different from the position of this means and determining the difference of the output signal of the both means. CONSTITUTION:A piezoelectric element 2 of the bioinformation detecting means 1 converts the various pressure changes, such as rider's heart beats applied to the embedded part, to electric signals. A filter circuit 3 filters the signals of the frequency bands corresponding to the heart beats. An amplifier circuit 4 amplifies the electric signals past the filter circuit 3 and a smoothing circuit 5 rectifies and integrates the amplified signals. A piezoelectric element 7 of the vibration sensing device 6 converts the vibrations, exclusive of the bioinformation of the rider, to electric signals. The filter circuit 8, the amplifier circuit 9 and the smoothing circuit 10 act similarly as the bioinformation detecting means 1. A subtracting means 11 subtracts the signals outputted by the vibration sensing means 6 from the signals outputted by the bioinformation detect means 1. A heart beat detecting means 12 detects the heart beat information included in the signals outputted by the subtracting means 11.
1,229,888. Vaccines. D. JACHERTZ. 19 June, 1968 [19 June, 1967], No. 29232/68. Heading A5B. Vaccines which are antigen-free and comprise aqueous suspensions of informationally active ribonucleic acid are prepared by stimulating with an antigen corresponding to the required informationally active RNA as system of immunologically competent cells or a cellfree system obtained therefrom, and isolating an aqueous suspension of the informationally active RNA. The vaccine may also contain an adjuvant such as aluminium hydroxide or phosphate and/or a pharmaceutically suitable carrier. The immunologically competent cells may be from human or animal lymphs, lymph nodes, spleen, peritoneal exudates and pheripheral leukocytes (blood). The antigen used may be from bacteria, viruses or their subunits or snake poison, e.g. tetanus and diphtheria toxin; the products of metabolism or degradation of Bordetella pertussio, Mycobacterlium tuberculosis, salmonellae, shigellae, brucellae; influenza, influenza haemagglutinim, polio viruses or their protein envelope, measles, rabies, foot and mouth disease, smallpox, swine fever, distemper, hepatitis contagiosa canis and encephalitis viruses.
[GB1229888A]
The present invention relates to a medicinal composition using pure natural vegetable medicine as main medicinal components with the effects for resolving toxin, eliminating acne and removing speckles. The medicinal composition is a preparation prepared from the raw materials of 40 to 1000 portions by weight of dandelion, 50 to 1100 portions by weight of climbing groundsel, 50 to 1100 portions by weight of arborvitae leaf, 50 to 1100 portions by weight of sargentgloryvine, 50 to 1100 portions by weight of bupleurum root, 40 to 1000 portions by weight of Armand clematis stem, 50 to 1100 portions by weight of dahurian angelica and 10 to 360 portions by weight of honeylocust thorn. The medicinal composition has the main functions and the main indications for expelling wind, clearing heat, resolving toxin and eliminating acne and is used for acne and chloasma caused by wind-heat counterflow ascension. The medicinal composition has the obvious effects for resisting bacteria, clearing heat, removing toxicity, eliminating pox, moistening the skin, moistening the intestines, relaxing the bowel, resisting inflammation and reducing swelling. The clinical trial results also indicate that the medicinal composition has certain curative effects on an abnormal tongue image and abnormal pulse manifestation. The medicinal composition can be applied to patients with idiopathic and secondary chloasma of traditional Chinese medicine syndrome differentiation of liver-kidney yin vacuity, blood stagnation and blood stasis, and comedo patients with first-degree acne and second-degree acne which is mainly represented by comedo, papule and pustule who belongs to traditional Chinese medicine syndrome differentiation of lung channel wind-heat, gastrointestinal damp-heat.
A pragmatic, cluster randomized trial in 45 Mayo Clinic primary care practices will be conducted over a period of 6 months with 6 months of follow up. Care teams will be randomized 1:1 to intervention or usual care, stratified by region and patient volume. In the intervention arm, the DULCE score will be used to alert consenting providers to the likelihood of advanced liver disease with a recommendation for a FibroTest-ActiTest. The primary endpoint will be detection of advanced liver disease. Secondary outcomes will include completion of noninvasive fibrosis assessment tests and hepatology referral within 180 days of ECG, new diagnosis of liver disease stratified by etiology (nonalcoholic fatty liver disease, alcohol-associated liver disease, hepatitis C, and others) and severity (compensated with and without clinically-significant portal hypertension, and decompensated disease), initiation of prophylactic nonselective beta-blockers and imaging for hepatocellular carcinoma surveillance, according to published society guidelines. Post-study surveys to participating clinicians will be applied.
BACKGROUND: The VASCADE MVP venous vascular closure system is commonly used for percutaneous venotomy closure in catheter-based procedures utilizing sheath sizes 6-12 French. However, its application with larger sheaths such as ones required in left atrial appendage occlusion (LAAO) has yet to be explored.
AIMS: This study compared the efficacy and safety of VASCADE MVP versus conventional Figure-of-8 sutures (Fo8) for femoral venotomy closure in patients undergoing Watchman LAAO.
METHODS: This single-center retrospective analysis included patients who underwent post-LAAO femoral venotomy closure with either VASCADE MVP or Fo8 sutures. The primary efficacy endpoint was time to hemostasis (TTH). Primary safety endpoints were 30-day access site-related readmissions and major complications. Minor access-site-related complications were also assessed.
RESULTS: 107 patients underwent post-LAAO femoral venotomy closure with VASCADE MVP, of which 101 were successful (94.4%). 99 patients underwent conventional closure with Fo8 sutures and supplemental manual pressure. Baseline characteristics were similar between groups. TTH was significantly shorter with VASCADE MVP (152.9 vs. 335.8 s, p = 0.001). Major safety outcomes were comparable. However, the conventional group experienced a higher incidence of ecchymosis (16.2% vs 4.7%, p = 0.007) and 30-day all-cause readmission (18.2% vs 8.4%, p = 0.038).
CONCLUSIONS: VASCADE MVP significantly reduced TTH compared to Fo8 sutures after LAAO. While demonstrating a similar safety profile, VASCADE MVP may offer a more efficient approach to femoral vein closure in this patient population.